Ping Chen

US Patent:

6385748, May 7, 2002

Filed:

Mar 30, 1999

Appl. No.:

09/281370

Inventors:

Ping Chen - San Jose CA

Assignee:

NEC Electronics, Inc. - Santa Clara CA

International Classification:

G01R 3128

US Classification:

714724, 365201

Abstract:

A method and circuit for allowing direct access logic testing in integrated circuits. In one embodiment, an interface between integrated circuit core logic and integrated circuit user-defined logic is exposed, and the integrated circuit core logic and the integrated circuit user-defined logic is tested via the exposed interface. In another embodiment, an integrated circuit has logic selection circuitry connected with core logic and user-defined logic. The logic selection circuitry is used to selectively test the core logic and user-defined logic.

US Patent:

6653304, Nov 25, 2003

Filed:

Feb 8, 2001

Appl. No.:

09/779109

Inventors:

Katerina Leftheris - Skillman NJ
Hong Wu - Lawrenceville NJ
Stephen Wrobleski - Whitehouse Station NJ
Ping Chen - Belle Mead NJ
John Hynes - Washington Crossing PA
John Tokarski - Princeton NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D40312

US Classification:

5142328, 514292, 544126, 546 81

Abstract:

Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.

US Patent:

6916809, Jul 12, 2005

Filed:

Dec 20, 2002

Appl. No.:

10/325009

Inventors:

Ping Chen - Belle Mead NJ, US
Edwin J. Iwanowicz - West Windsor NJ, US
Scott H. Watterson - Pennington NJ, US
Henry Gu - Bordentown NJ, US
Yufen Zhao - Pennington NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D471/14
C07D471/04
A61K031/4375
A61P019/02
A61P017/06

US Classification:

5142305, 51425505, 514256, 514293, 544105, 544333, 544405, 544 60, 544126, 544361, 544250, 546 81, 540575

Abstract:

Compounds having the formula (I), wherein Ris selected from H, OH and NH; Ris selected from ═O and ═S; W is —C(═O)—, —S(═O)—, or —S(O)—; or W may be —CH— if X is —C(═O)—; X is selected from —CH—, —N(R)—, and —O—, except that when W is —CH—, X is —C(═O)—; Y is a bond or —C(R)(R)—; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X, X, X, X, X, X, X, X, X, Xand Xare selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.

US Patent:

7064203, Jun 20, 2006

Filed:

Dec 22, 2004

Appl. No.:

11/019899

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Wen-Ching Han - Newtown PA, US
Ping Chen - Belle Mead NJ, US
Edward H. Ruediger - Greenfield Park, CA
Harold Mastalerz - Guilford CT, US
Brian E. Fink - Princeton Junction NJ, US
Derek J. Norris - Pennington NJ, US

Assignee:

Bristol Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53
A61P 19/02

US Classification:

544183, 514243

Abstract:

The present invention provides compounds of formula IThe compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

US Patent:

7141571, Nov 28, 2006

Filed:

Dec 22, 2004

Appl. No.:

11/019901

Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newton PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7151176, Dec 19, 2006

Filed:

Oct 19, 2005

Appl. No.:

11/253832

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Wen-Ching Han - Newtown PA, US
Yufen Zhao - Pennington NJ, US
Ping Chen - Belle Mead NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53
A61P 19/02
A61P 35/00

US Classification:

544183, 514243

Abstract:

The present invention provides compounds of formula IThe compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7297695, Nov 20, 2007

Filed:

Jun 26, 2006

Appl. No.:

11/426479

Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newtown PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/06
C07D 401/14
A61K 31/53
A61P 35/00

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7312209, Dec 25, 2007

Filed:

Dec 20, 2002

Appl. No.:

10/324306

Inventors:

Edwin J. Iwanowicz - West Windsor NJ, US
Scott H. Watterson - Pennington NJ, US
Ping Chen - Belle Mead NJ, US
T. G. Murali Dhar - Newtown PA, US
Henry H. Gu - Bordentown NJ, US
Yufen Zhao - Pennington NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 417/00
C07D 265/36
C07D 413/00
C07D 401/00
C07D 239/02

US Classification:

514218, 5142282, 5142305, 5142328, 51425303, 51426621, 514269, 514274, 514297, 540553, 544 61, 544105, 544126, 544284, 544315, 544319, 544361, 546103

Abstract:

Compounds having the formula (I),.